LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Kymera Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

87 1.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

83.94

Max

87.81

Galvenie mērījumi

By Trading Economics

Ienākumi

18M

-69M

Pārdošana

32M

34M

EPS

-0.71

Peļņas marža

-201.467

Darbinieki

253

EBITDA

18M

-67M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+37.02% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 11. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-979M

6.1B

Iepriekšējā atvēršanas cena

85.97

Iepriekšējā slēgšanas cena

87

Ziņu noskaņojums

By Acuity

50%

50%

146 / 342 Rangs Healthcare

Kymera Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Par Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat